HISTOLOGICAL REGRESSION OF BREAST-CANCER AFTER PRIMARY (NEOADJUVANT) CHEMOTHERAPY

被引:135
|
作者
SINN, HP [1 ]
SCHMID, H [1 ]
JUNKERMANN, H [1 ]
HUOBER, J [1 ]
LEPPIEN, G [1 ]
KAUFMANN, M [1 ]
BASTERT, G [1 ]
OTTO, HF [1 ]
机构
[1] UNIV HEIDELBERG, INST PATHOL, W-6900 HEIDELBERG, GERMANY
关键词
D O I
10.1055/s-2007-1022338
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Primary (neoadjuvant) chemotherapy of locally advanced breast carcinomas is performed to locally reduce the tumour mass and to improve the operability. Recently, the indication for primary chemotherapy has. been extended for preoperative treatment in breast conserving surgery. In an ongoing clinical trial we examined the resection specimens of 51 mammary carcinomas after primary chemotherapy. These patients had received a neoadjuvant therapy with epirubicine/cyclophosphamide for size reduction of large (> 3 cm) but operable tumours (pretreatment median tumour size 4.5 cm by mammography). The tumour response was evaluated pathologically and copared with the clinical tumour regression that was observed in over two-thirds of all cases. We classified the regressive changes using a semiquantitative scoring system from 0 to 4 (0 = no effect, 1 = resorption and tumour sclerosis, 2 = minimal residual invasive tumour [< 0.5 cm], 3 = residual noninvasive tumour only, 4 = no tumour detectable). The aim of this study was to evaluate the improvement of operability objectively and to correlate the histology of the primary tumour with the response to treatment. With invasive lobular carcinomas, the tumour size after therapy was reduced less than average and irrespective of the amount of histological tumour cell reduction, largely due to the stromal content of these neoplasms. Invasive ductal carcinomas with extensive or predominant intraductal component also underwent only a slight decrease in tumour size; this was because of the lack of tumour response with the intraductal component. Well differentiated tubular carcinomas were particularly resistant to primary chemotherapy. We conclude that the response of mammary carcinomas to primary chemotherapy can at least partially be explained by the tumour differentiation and is therefore to some extent predictable with careful evaluation of the pretreatment punch biopsy. The semiquantitative histological evaluation score suggested in this article permits the classification of the treatment effects and is therefore useful for further therapy planning.
引用
收藏
页码:552 / 558
页数:7
相关论文
共 50 条
  • [31] Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
    von Minckwitz, Gunter
    Schmitt, Wolfgang D.
    Loibl, Sibylle
    Mueller, Berit M.
    Blohmer, Jens U.
    Sinn, Bruno V.
    Eidtmann, Holger
    Eiermann, Wolfgang
    Gerber, Bernd
    Tesch, Hans
    Hilfrich, Joern
    Huober, Jens
    Fehm, Tanja
    Barinoff, Jana
    Ruediger, Thomas
    Erbstoesser, Erhard
    Fasching, Peter A.
    Karn, Thomas
    Mueller, Volkmar
    Jackisch, Christian
    Denkert, Carsten
    CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4521 - 4531
  • [32] HIGH COMPLETE REMISSION RATES WITH PRIMARY NEOADJUVANT INFUSIONAL CHEMOTHERAPY FOR LARGE EARLY BREAST-CANCER
    SMITH, IE
    WALSH, G
    JONES, A
    PRENDIVILLE, J
    JOHNSTON, S
    GUSTERSON, B
    RAMAGE, F
    ROBERTSHAW, H
    SACKS, N
    EBBS, S
    MCKINNA, JA
    BAUM, M
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) : 424 - 429
  • [33] ADJUVANT AND NEOADJUVANT TREATMENT OF BREAST-CANCER WITH CHEMOTHERAPY AND OR ENDOCRINE THERAPY
    BONADONNA, G
    VALAGUSSA, P
    BRAMBILLA, C
    MOLITERNI, A
    ZAMBETTI, M
    FERRARI, L
    SEMINARS IN ONCOLOGY, 1991, 18 (06) : 515 - 524
  • [34] Breast Cancer: Prognosis after neoadjuvant Chemotherapy
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (07)
  • [35] PRELIMINARY-RESULTS OF NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST-CANCER
    SCHMIDT, C
    EGGER, H
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 873 - 874
  • [36] STAGE III BREAST-CANCER - IS NEOADJUVANT CHEMOTHERAPY ALWAYS NECESSARY
    FRANK, JL
    MCCLISH, DK
    DAWSON, KS
    BEAR, HD
    JOURNAL OF SURGICAL ONCOLOGY, 1992, 49 (04) : 220 - 225
  • [37] The histological and biological markers to predict early distant metastasis after neoadjuvant chemotherapy in breast cancer
    Tokuda, E.
    Arakawa, A.
    Yao, T.
    Takahashi, Y.
    Horimoto, Y.
    Shimizu, H.
    Kosaka, T.
    Abe, I
    Senuma, K.
    Nakai, K.
    Miura, H.
    Saito, M.
    Kasumi, F.
    VIRCHOWS ARCHIV, 2009, 455 : 190 - 191
  • [38] PRIMARY (NEOADJUVANT) CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH PRIMARY RADIOTHERAPY ALONE IN STAGE IIB-IIIA BREAST-CANCER
    SEMIGLAZOV, VF
    TOPUZOV, EE
    BAVLI, JL
    MOISEYENKO, VM
    IVANOVA, OA
    SELEZNEV, IK
    ORLOV, AA
    BARASH, NY
    GOLUBEVA, OM
    CHEPIC, OF
    ANNALS OF ONCOLOGY, 1994, 5 (07) : 591 - 595
  • [39] Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy
    K. Wasser
    H. Sinn
    C. Fink
    S. Klein
    H. Junkermann
    H. Lüdemann
    I. Zuna
    S. Delorme
    European Radiology, 2003, 13 : 1213 - 1223
  • [40] Accuracy of tumor size measuremen in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy
    Wasser, K
    Sinn, HP
    Fink, C
    Klein, SK
    Junkermann, H
    Lüdemann, HP
    Zuna, I
    Delorme, S
    EUROPEAN RADIOLOGY, 2003, 13 (06) : 1213 - 1223